Non-drug treatment Target the Drake Institute as a potential partner or supplier for non-pharmacological ADHD and autism treatment technologies, leveraging their focus on brain-based therapies and FDA approved QEEG brainmapping and neurofeedback within their FullCare program.

Clinical scale Position offerings to align with their established treatment model that has served over 12,000 patients across 35 years, emphasizing scalable, tech-enabled solutions that fit into a high-touch medical clinic setting.

Tech stack Highlight compatibility or integration opportunities with their current tech stack (AWS, Microsoft 365, Azure, iCIMS, Piwik PRO) for patient data management, analytics, and marketing automation to improve outcomes and operational efficiency.

Growth readiness Present services that support expansion or replication of the FullCare program, including clinician training, telemedicine components, and software that enables standardized Neurofeedback protocols for broader patient reach.

Revenue profile Acknowledge the clinic’s current revenue under one million dollars and tailor value propositions around cost-effective, scalable tools and partnerships that offer clear ROI and potential for revenue growth without large capital expenditure.